Author: Bloomberg News

Article content

Investment bankers are urging Toronto-listed companies to buy a business or raise some money as deal volumes in Canada have fallen to their lowest levels in 23 years.

Article content

Article content

Equity and equity-linked offerings in Canada fell for the third straight year to hit their lowest point since 2001, according to league tables compiled by Bloomberg. There were 236 deals in 2024, raising $17.2 billion, compared with $19.8 billion in 2023.

Article content

The activity stands in sharp contrast to the United States, where such offerings have climbed for the third straight year, data compiled by Bloomberg show.

“We need corporate Canada to become greater risk takers,” said Peter Miller, head of equity capital markets at Bank of Montreal (BMO) Capital Markets in Toronto. “We just need corporate Canada to, you know, want to take some risks, strap on some capital projects and do more mergers and acquisitions to fuel growth.”

Article content

Miller said that while the number of deals dropped in 2024, the proportion of so-called clean deals rose, indicating investors have appetite for more. The problem is not demand but supply, he said.

In a clean deal, banks are able to smoothly sell securities of a transaction they underwrote, whereas in a hung deal they may need to offer deeper discounts or risk being stuck with unsold inventory.

“I think that every deal that we’ve done this year has been a green shoot,” said Nitin Babbar, Royal Bank of Canada (RBC) Capital Markets global co-head of equity capital markets, adding that investors are looking to buy into stock offerings for companies looking to grow. “Every deal that’s come has been very, very well received.”

Article content

RBC Capital Markets topped Canadian equity and equity-linked league tables this year with mandates to raised $2.8 billion for companies. BMO Capital Markets wasn’t far behind, helping raise $2.7 billion for firms.

RBC and BMO have dominated the rankings for five straight years — one of the two banks have finished top of the table every year since 2019. This year, those two banks accounted for 34 per cent of the total offerings.

Miller pointed to two bright spots in the Canadian equity offerings market this year. There was a sharp uptick in the number of mining companies raising equity capital. And there was — after a nearly 18-month dry spell — an initial public offering on the Toronto Stock Exchange. Groupe Dynamite Inc. raised $300 million in a November deal that valued the firm at $2.3 billion.

There is also some hope that lower capital costs will spur activity in Canada, where the central bank has cut interest rates five times this year and been more aggressive in easing monetary policy than the US.

“I think we’re sitting in an environment where rates have come down materially,” RBC’s Babbar said. “The cost of capital, as a result, is lower and what we’re seeing is more growth.”

Bloomberg.com

Article content

Article content

Bausch + Lomb said it authorized management and advisers to explore a potential sale of the eye health company after shares dropped over reports of faltering deal talks with a group of private equity firms.

Article content

Article content

The company said a sale was “one of several options being explored to complete a full separation from Bausch Health Companies Inc.,” in a statement on Thursday. “That process is ongoing, and there can be no assurance that it will result in a transaction.”

Article content

The company said it typically didn’t comment on deal negotiations but wanted to issue a response to a request for information from the Canadian Investment Regulatory Organization (CIRO). “CIRO requested confirmation of a potential sale process given stock volatility often associated with market rumours. Bausch + Lomb does not intend to provide additional detail until further disclosure is appropriate or necessary,” the company said.

Article content

The company is traded on both the New York Stock Exchange and Toronto Stock Exchange. The shares have gained 6.5 per cent this year through Wednesday’s close in New York. The company’s stock tumbled yesterday after the Financial Times reported that Blackstone could pull out of a joint takeover bid for the eye care company, citing unidentified people familiar with matter.

If Bausch Health sells the eye care company it majority owns, it would end a years-long battle over the separation of the eye-care business. The split has been in the works since as early as 2020, but it ran aground due to disagreements between shareholders and lenders, as well as questions about Bausch Health’s financial health.

Article content

Bausch Health has about US$21 billion in debt, according to data compiled by Bloomberg. Questions about whether the company could remain solvent without Bausch + Lomb have complicated the separation.

Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic competition in the coming years as patent protection wanes.

Bausch Health was formerly known as Valeant Pharmaceuticals. It rebranded in 2018 after the company came under government scrutiny for raising drug prices and a former executive was convicted of accepting a bribe.

Bloomberg.com

Article content